Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.

Schmitz S, Hamoir M, Reychler H, Magremanne M, Weynand B, Lhommel R, Hanin FX, Duprez T, Michoux N, Rommel D, Lonneux M, Cappoen N, Gillain A, Machiels JP.

Ann Oncol. 2013 Sep;24(9):2261-6. doi: 10.1093/annonc/mdt180. Epub 2013 May 23.

PMID:
23704200
[PubMed - indexed for MEDLINE]
Free Article
2.

FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.

Kitagawa Y, Sano K, Nishizawa S, Nakamura M, Ogasawara T, Sadato N, Yonekura Y.

Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):63-71. Epub 2002 Oct 26.

PMID:
12483411
[PubMed - indexed for MEDLINE]
3.

Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.

van Dijk LK, Boerman OC, Franssen GM, Lok J, Kaanders JH, Bussink J.

J Nucl Med. 2014 Oct;55(10):1665-70. doi: 10.2967/jnumed.114.141762. Epub 2014 Sep 18.

PMID:
25236350
[PubMed - indexed for MEDLINE]
4.

18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.

Hoeben BA, Troost EG, Bussink J, van Herpen CM, Oyen WJ, Kaanders JH.

Nuklearmedizin. 2014;53(2):60-6. doi: 10.3413/Nukmed-0625-13-09. Epub 2014 Jan 28.

PMID:
24468965
[PubMed - indexed for MEDLINE]
5.

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.

Bahassi el M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O.

Eur J Cancer. 2013 Jul;49(10):2345-55. doi: 10.1016/j.ejca.2013.03.005. Epub 2013 Apr 8.

PMID:
23578570
[PubMed - indexed for MEDLINE]
6.

Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.

Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X.

Clin Cancer Res. 2010 Apr 1;16(7):2095-105. doi: 10.1158/1078-0432.CCR-09-2495. Epub 2010 Mar 9.

PMID:
20215534
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.

McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD.

Head Neck. 2004 Oct;26(10):890-6.

PMID:
15390197
[PubMed - indexed for MEDLINE]
8.

Preoperative assessment of cervical lymph nodes in head and neck cancer with fluorine-18 fluorodeoxyglucose using a dual-head coincidence camera: a pilot study.

Stokkel MP, ten Broek FW, van Rijk PP.

Eur J Nucl Med. 1999 May;26(5):499-503.

PMID:
10382094
[PubMed - indexed for MEDLINE]
9.

Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.

Okano S, Yoshino T, Fujii M, Onozawa Y, Kodaira T, Fujii H, Akimoto T, Ishikura S, Oguchi M, Zenda S, de Blas B, Tahara M, Beier F.

Jpn J Clin Oncol. 2013 May;43(5):476-82. doi: 10.1093/jjco/hyt030. Epub 2013 Mar 10.

PMID:
23479383
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

Atkinson DM, Clarke MJ, Mladek AC, Carlson BL, Trump DP, Jacobson MS, Kemp BJ, Lowe VJ, Sarkaria JN.

Head Neck. 2008 Jun;30(6):790-9. doi: 10.1002/hed.20770.

PMID:
18286491
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.

Farber LA, Benard F, Machtay M, Smith RJ, Weber RS, Weinstein GS, Chalian AA, Alavi A, Rosenthal DI.

Laryngoscope. 1999 Jun;109(6):970-5.

PMID:
10369292
[PubMed - indexed for MEDLINE]
12.

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B.

Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review.

PMID:
16050785
[PubMed - indexed for MEDLINE]
13.

Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.

Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, Peeters WJ, Kaanders JH, Bussink J, Boerman OC.

Int J Cancer. 2011 Aug 15;129(4):870-8. doi: 10.1002/ijc.25727. Epub 2010 Dec 1.

PMID:
20957635
[PubMed - indexed for MEDLINE]
14.

Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.

Eder J, Simonitsch-Klupp I, Trautinger F.

Eur J Dermatol. 2013 Sep-Oct;23(5):658-62. doi: 10.1684/ejd.2013.2153.

PMID:
24135559
[PubMed - indexed for MEDLINE]
15.

A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography.

Hyde NC, Prvulovich E, Newman L, Waddington WA, Visvikis D, Ell P.

Oral Oncol. 2003 Jun;39(4):350-60.

PMID:
12676254
[PubMed - indexed for MEDLINE]
16.

PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.

Kostakoglu L, Goldsmith SJ.

J Nucl Med. 2004 Jan;45(1):56-68. Review.

PMID:
14734674
[PubMed - indexed for MEDLINE]
Free Article
17.

FDG-PET. A possible prognostic factor in head and neck cancer.

Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M.

Br J Cancer. 2002 Feb 12;86(4):512-6.

PMID:
11870529
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Sequential FDG-PET/CT after neoadjuvant chemotherapy is a predictor of histopathologic response in patients with head and neck squamous cell carcinoma.

Kikuchi M, Shinohara S, Nakamoto Y, Usami Y, Fujiwara K, Adachi T, Hori SY, Tona Y, Yamazaki H, Imai Y, Naito Y.

Mol Imaging Biol. 2011 Apr;13(2):368-77. doi: 10.1007/s11307-010-0364-3.

PMID:
20552285
[PubMed - indexed for MEDLINE]
19.

Early evaluation of the response to radiotherapy of patients with squamous cell carcinoma of the head and neck using 18FDG-PET.

Nam SY, Lee SW, Im KC, Kim JS, Kim SY, Choi SH, Ryu JS, Moon DH, Oh SJ, Yi BY, Kim JH, Ahn SD, Shin SS, Kim SB, Choi EK, Lee BJ.

Oral Oncol. 2005 Apr;41(4):390-5.

PMID:
15792611
[PubMed - indexed for MEDLINE]
20.

Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma.

Balogova S, Périé S, Kerrou K, Grahek D, Montravers F, Angelard B, Susini B, El Chater P, St Guily JL, Talbot JN.

Mol Imaging Biol. 2008 Nov-Dec;10(6):364-73. doi: 10.1007/s11307-008-0155-2. Epub 2008 Jul 31.

PMID:
18668293
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk